Roche Holding saw its EPS decline at a compound rate of 6.7% per year, over the last three years. This reduction in EPS is ...

With the U.S. election result and the German government’s collapse, the lagging European economy is at a crossroads.

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

In April 2021, Novartis AG announced a collaboration with Artios Pharma ... and Strategic Transformation. Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been ...

DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...

Digital Pathology Market. In 2023, the digital pathology market is expected to be valued at USD 7,035.8 million USD. By 2033, the market is anticipated to reach USD 24,961.8 milli ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target ...

The Swiss People's Party (SVP) - which is the largest in the ruling coalition of four parties - launched the anti-immigration ...

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Roche Holding AG (RHHBY) or AbbVie (ABBV). But which of these two stocks offers value investors a ...

For some of Europe’s biggest exporters, the prospect of a stronger dollar offers a silver lining in the uncertain outlook ...

Global Central Nervous System Therapeutics Market is valued at approximately USD 143.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...